NanoBioRad

Our team is developing a rapid, quantitative DNA damage detection platform to revolutionise how cancer therapies are evaluated. With expertise in cancer biology, radiation oncology, and molecular diagnostics, we’re addressing the critical gap in real-time, scalable DNA damage measurement. Traditional assays are slow and ambiguous, and so we’re building technology that helps clinicians and pharmaceutical companies make faster, smarter decisions.

Backed by experience across academia, biotech, and translational research, our team is united by a shared mission: to reduce uncertainty, improve drug specificity, and ultimately personalise cancer treatment. We’re turning DNA damage from a lagging indicator into an actionable biomarker.

Want to learn more or chat with the team? Reach out to NanoBioRad’s team leader, Jake Atkinson via jake.atkinson@mymail.unisa.edu.au

If you would like an introduction – we’re here to help! Contact the ON team via on@csiro.au